The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models

Hallmarks of Cancer: The Next Generation

Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590

XDS

Kabsch, W. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909047337 · Cited by 16,463

Refinement of Macromolecular Structures by the Maximum-Likelihood Method

Murshudov, G. N., Vagin, A. A., & Dodson, E. J. (1997) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444996012255 · Cited by 14,796

MOLREP : an Automated Program for Molecular Replacement

Vagin, A. A., & Teplyakov, A. (1997) · Journal of Applied Crystallography · doi:10.1107/s0021889897006766 · Cited by 4,756

The landscape of somatic copy-number alteration across human cancers

Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,407

Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy

Czabotar, P. E., Lessene, G., Strasser, A., & Adams, J. M. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3722 · Cited by 3,219

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

Souers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S. L., Catron, N. D., Chen, J., Dayton, B. D., Ding, H., Enschede, S. H., Fairbrother, W. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3048 · Cited by 3,058

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

Roberts, A. W., Davids, M. S., Pagel, J. M., Kahl, B. S., Puvvada, S. D., Gerecitano, J. F., Kipps, T. J., Anderson, M. A., Brown, J. R., Gressick, L. A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1513257 · Cited by 1,930

Differential Targeting of Prosurvival Bcl-2 Proteins by Their BH3-Only Ligands Allows Complementary Apoptotic Function

Chen, L., Willis, S. N., Wei, A., Smith, B. J., Fletcher, J. I., Hinds, M. G., Colman, P. M., Day, C. L., Adams, J. M., & Huang, D. C. S. (2005) · Molecular Cell · doi:10.1016/j.molcel.2004.12.030 · Cited by 1,816

Elucidating therapeutic molecular targets in premenopausal Asian women with recurrent breast cancers

Yap, Y. S., Singh, A., Lim, J. H. C., Ahn, J., Jung, K.-H., Kim, J., Dent, R. A., Ng, R. C. H., Kim, S., & Chiang, D. Y. (2018) · npj Breast Cancer · doi:10.1038/s41523-018-0070-x · Cited by 28

Discovery of 3,5-Dimethyl-4-Sulfonyl-1H-Pyrrole-Based Myeloid Cell Leukemia 1 Inhibitors with High Affinity, Selectivity, and Oral Bioavailability

Zhu, P., Yu, Z.-Z., Lv, Y.-F., Zhao, J., Tong, Y.-Y., You, Q., & Jiang, Z. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00682 · Cited by 28

The deubiquitinating enzyme OTUD1 antagonizes BH3-mimetic inhibitor induced cell death through regulating the stability of the MCL1 protein

Wu, L., Lin, Y., Feng, J., Qi, Y., Wang, X., Lin, Q., Shi, W., Zheng, E., Wang, W., Hou, Z., et al. (2019) · Cancer Cell International · doi:10.1186/s12935-019-0936-5 · Cited by 28

Next-Generation Sequencing Reveals Potential Predictive Biomarkers and Targets of Therapy for Urothelial Carcinoma in Situ of the Urinary Bladder

Garczyk, S., Ortiz‐Brüchle, N., Schneider, U., Lurje, I., Guricová, K., Gaisa, N. T., Lorsy, E., Lindemann-Docter, K., Heidenreich, A., & Knüchel, R. (2019) · American Journal Of Pathology · doi:10.1016/j.ajpath.2019.10.004 · Cited by 28

Molecular insights and clinical implications for the tumor suppressor role of SCFFBXW7 E3 ubiquitin ligase

Qi, Y., Rezaeian, A.-H., Wang, J., Huang, D., Chen, H., Inuzuka, H., & Wei, W. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189140 · Cited by 27

ATF4 destabilizes RET through nonclassical GRP78 inhibition to enhance chemosensitivity to bortezomib in human osteosarcoma

Luo, J., Xia, Y., Yin, Y., Luo, J., Liu, M., Zhang, H., Zhang, C., Zhao, Y., Yang, L., & Kong, L. (2019) · Theranostics · doi:10.7150/thno.36818 · Cited by 27

Pan-RAF inhibition induces apoptosis in acute myeloid leukemia cells and synergizes with BCL2 inhibition

Tambe, M., Karjalainen, E., Vähä-Koskela, M. J. V., Bulanova, D. R., Gjertsen, B. T., Kontro, M., Porkka, K., Heckman, C. A., & Wennerberg, K. (2020) · Leukemia · doi:10.1038/s41375-020-0972-0 · Cited by 27

Sequential combinations of chemotherapeutic agents with BH3 mimetics to treat rhabdomyosarcoma and avoid resistance

Alcon, C., Manzano-Muñoz, A., Prada, E., Mora, J., Soriano, A., Guillén, G., Gallego, S., Roma, J. M., Samitier, J., Villanueva, A., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-02887-y · Cited by 29

Inhibition of the anti-apoptotic protein MCL-1 severely suppresses human hematopoiesis

Bohler, S., Afreen, S., Fernández‐Orth, J., Demmerath, E.-M., Molnár, C., Wu, Y., Weiss, J. M., Mittapalli, V. R., Konstantinidis, L., Schmal, H., et al. (2020) · Haematologica · doi:10.3324/haematol.2020.252130 · Cited by 27

Targeting the BCL-2-regulated apoptotic pathway for the treatment of solid cancers

Fairlie, W. D., & Lee, E. F. (2021) · Biochemical Society Transactions · doi:10.1042/bst20210750 · Cited by 28

Inhibitors of Bcl-2 and Bruton’s tyrosine kinase synergize to abrogate diffuse large B-cell lymphoma growth in vitro and in orthotopic xenotransplantation models

Bertram, K., Leary, P., Boudesco, C., Fullin, J., Stirm, K., Dalal, V., Zenz, T., Tzankov, A., & Mueller, A. (2021) · Leukemia · doi:10.1038/s41375-021-01470-4 · Cited by 27

Pro-apoptotic and anti-apoptotic regulation mediated by deubiquitinating enzymes

Choi, H., & Baek, K. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04132-5 · Cited by 27

Mcl-1 regulates reactive oxygen species via NOX4 during chemotherapy-induced senescence

Demelash, A., Pfannenstiel, L. W., Liu, L., & Gastman, B. (2017) · Oncotarget · doi:10.18632/oncotarget.15962 · Cited by 27

BH3 mimetics induce apoptosis independent of DRP-1 in melanoma

Mukherjee, N., Strosnider, A., Vagher, B., Lambert, K. A., Slaven, S., Robinson, W. A., Amato, C. M., Couts, K. L., Bemis, J. G. T., Turner, J. A., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0932-z · Cited by 27

Overexpression of Antiapoptotic MCL-1 Predicts Worse Overall Survival of Patients With Non-small Cell Lung Cancer

Nakano, T., Go, T., Nakashima, N., Liu, D., & Yokomise, H. (2020) · Anticancer Research · doi:10.21873/anticanres.14035 · Cited by 27

Therapeutics Targeting the Core Apoptotic Machinery

Hamilton, C., Fox, J. P., Longley, D. B., & Higgins, C. A. (2021) · Cancers · doi:10.3390/cancers13112618 · Cited by 26

Heterogeneity of Cellular Senescence, Senotyping, and Targeting by Senolytics and Senomorphics in Lung Diseases

Ozdemir, S. A., Faizan, M. I., Kaur, G., Shaikh, S. B., Islam, K. U., & Rahman, I. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26199687 · Cited by 28

Combined Bcl-2/Src inhibition synergize to deplete stem-like breast cancer cells

Sun, Q., Wang, Y., & Desgrosellier, J. S. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.05.004 · Cited by 26

Mcl-1 as a “barrier” in cancer treatment: Can we target it now?

Pervushin, N. V., Senichkin, V. V., Zhivotovsky, B., & Kopeina, G. S. (2020) · International review of cytology · doi:10.1016/bs.ircmb.2020.01.002 · Cited by 26

MCL1 nuclear translocation induces chemoresistance in colorectal carcinoma

Fu, D., Pfannenstiel, L., Demelash, A., Phoon, Y. P., Mayell, C., Cabrera, C., Liu, C., Zhao, J., Dermawan, J. K. T. K., Patil, D. T., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-021-04334-y · Cited by 28

Heightened apoptotic priming of vascular cells across tissues and life span predisposes them to cancer therapy–induced toxicities

Spetz, J. K. E., Florido, M. H. C., Fraser, C. S., Qin, X., Choiniere, J., Yu, S. J., Singh, R., Friesen, M., Rubin, L. L., Salem, J., et al. (2022) · Science Advances · doi:10.1126/sciadv.abn6579 · Cited by 26

High-throughput chemogenetic drug screening reveals PKC-RhoA/PKN as a targetable signaling vulnerability in GNAQ-driven uveal melanoma

Arang, N., Lubrano, S., Ceribelli, M., Rigiracciolo, D. C., Saddawi‐Konefka, R., Faraji, F., Ramirez, S. I., Kim, D., Tosto, F. A., Stevenson, E. J., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101244 · Cited by 26

Intrinsic apoptotic pathway activation increases response to anti-estrogens in luminal breast cancers

Williams, M. M., Lee, L., Werfel, T. A., Joly, M. M., Hicks, D. J., Rahman, B., Elion, D. L., McKernan, C., Sanchez, V. M., Estrada, M. V., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0072-x · Cited by 26

Wasabi 6‐(methylsulfinyl)hexyl isothiocyanate induces apoptosis in human colorectal cancer cells through p53‐independent mitochondrial dysfunction pathway

Yano, S., Wu, S., Sakao, K., & Hou, D. (2018) · BioFactors · doi:10.1002/biof.1431 · Cited by 26

ABT-199-mediated inhibition of Bcl-2 as a potential therapeutic strategy for nasopharyngeal carcinoma

Wang, Y., Wang, Y., Fan, X., Song, J., Wu, H., Han, J., Lu, L., Weng, X., & Nie, G. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.07.027 · Cited by 26

Therapeutic inhibition of Mcl-1 blocks cell survival in estrogen receptor-positive breast cancers

Williams, M. M., Elion, D. L., Rahman, B., Hicks, D. J., Sanchez, V. M., & Cook, R. S. (2019) · Oncotarget · doi:10.18632/oncotarget.27070 · Cited by 27

Phenethyl isothiocyanate synergistically induces apoptosis with Gefitinib in non–small cell lung cancer cells via endoplasmic reticulum stress‐mediated degradation of Mcl‐1

Zhang, Q., Chen, M., Cao, L., Ren, Y., Guo, X., Wu, X., & Xu, K. (2020) · Molecular Carcinogenesis · doi:10.1002/mc.23184 · Cited by 26

The interplay between cell death and senescence in cancer

Shimizu, K., Inuzuka, H., & Tokunaga, F. (2024) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2024.11.001 · Cited by 28

Myeloid cell leukemia-1 dependence in acute myeloid leukemia: a novel approach to patient therapy

Kadia, T. M., Kantarjian, H. M., & Konopleva, M. Y. (2019) · Oncotarget · doi:10.18632/oncotarget.26579 · Cited by 25

Overcoming MCL-1-driven adaptive resistance to targeted therapies

Wood, K. C. (2020) · Nature Communications · doi:10.1038/s41467-020-14392-z · Cited by 25

Targeting mitochondrial respiration and the BCL2 family in high‐grade MYC‐associated B‐cell lymphoma

Donati, G., Ravà, M., Filipuzzi, M., Nicoli, P., Cassina, L., Verrecchia, A., Doni, M., Rodighiero, S., Parodi, F., Boletta, A., et al. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13115 · Cited by 28

Venetoclax imparts distinct cell death sensitivity and adaptivity patterns in T cells

Ludwig, L. M., Hawley, K. M., Banks, D. B., Thomas-Toth, A. T., Blazar, B. R., McNerney, M. E., Leverson, J. D., & LaBelle, J. L. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04285-4 · Cited by 25

Chidamide and apatinib are therapeutically synergistic in acute myeloid leukemia stem and progenitor cells

Zhao, H., Jiang, Y., Lin, F., Zhong, M., Tan, J., Zhou, Y., Liu, L., Li, G., Deng, M., & Xu, B. (2022) · Experimental Hematology and Oncology · doi:10.1186/s40164-022-00282-1 · Cited by 25

Targeting a mitochondrial E3 ubiquitin ligase complex to overcome AML cell-intrinsic Venetoclax resistance

Nakao, F., Setoguchi, K., Semba, Y., Yamauchi, T., Nogami, J., Sasaki, K., Imanaga, H., Terasaki, T., Miyazaki, M., Hirabayashi, S., et al. (2023) · Leukemia · doi:10.1038/s41375-023-01879-z · Cited by 25

Evaluating venetoclax and its potential in treatment-naïve acute myeloid leukemia

Knight, T. E., Edwards, H. J., Taub, J. W., & Ge, Y. (2019) · Cancer Management and Research · doi:10.2147/cmar.s180724 · Cited by 26

Potent efficacy of MCL-1 inhibitor-based therapies in preclinical models of mantle cell lymphoma

Dengler, M. A., Teh, C. E., Thijssen, R., Gangoda, L., Lan, P., Herold, M. J., Gray, D. H. D., Kelly, G. L., Roberts, A. W., & Adams, J. M. (2019) · Oncogene · doi:10.1038/s41388-019-1122-x · Cited by 25

BCL2 Family Inhibitors in the Biology and Treatment of Multiple Myeloma

Gupta, V. A., Ackley, J. C., Kaufman, J. L., & Boise, L. (2021) · Blood and Lymphatic Cancer Targets and Therapy · doi:10.2147/blctt.s245191 · Cited by 27

ELP-dependent expression of MCL1 promotes resistance to EGFR inhibition in triple-negative breast cancer cells

Cruz-Gordillo, P., Honeywell, M. E., Harper, N. W., Leete, T., & Lee, M. J. (2020) · Science Signaling · doi:10.1126/scisignal.abb9820 · Cited by 24

Evasion of apoptosis and treatment resistance in squamous cell carcinoma of the head and neck

O’Leary, B., Skinner, H. D., Schoenfeld, J. D., Licitra, L. F., Tourneau, C. L., Esdar, C., Schröeder, A., Salmio, S., & Psyrri, A. K. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102773 · Cited by 26

Targeting the BCL2 Family: Advances and Challenges in BH3 Mimetic-Based Therapies

Mukherjee, N., Sheetz, J., & Shellman, Y. G. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26209859 · Cited by 24

CDK5 Inhibitor Downregulates Mcl-1 and Sensitizes Pancreatic Cancer Cell Lines to Navitoclax

Kour, S., Rana, S., Contreras, J. I., King, H. M., Robb, C. M., Sonawane, Y. A., Bendjennat, M., Crawford, A. J., Barger, C. J., Kizhake, S., et al. (2019) · Molecular Pharmacology · doi:10.1124/mol.119.116855 · Cited by 24

Truncated Bid Regulates Cisplatin Response via Activation of Mitochondrial Apoptosis Pathway in Ovarian Cancer

Dai, Y., Zhao, X., Li, F., Yuan, Y., Yan, D., Cao, H., Huang, X., Hu, Z., Ma, D., & Gao, Q. (2020) · Human Gene Therapy · doi:10.1089/hum.2019.206 · Cited by 24

The Heme-Regulated Inhibitor Pathway Modulates Susceptibility of Poor Prognosis B-Lineage Acute Leukemia to BH3-Mimetics

Smith, K. H., Budhraja, A., Lynch, J., Roberts, K. G., Panetta, J. C., Connelly, J. P., Turnis, M. E., Pruett‐Miller, S. M., Schuetz, J. D., Mullighan, C. G., et al. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0586 · Cited by 24

MNK1 and MNK2 enforce expression of E2F1, FOXM1, and WEE1 to drive soft tissue sarcoma

Ke, X., Chen, Y., Tham, V. Y.-Y., Lin, R. Y., Dakle, P., Nacro, K., Puhaindran, M. E., Houghton, P. J., Pang, A. S. L., Lee, V. K. M., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01661-4 · Cited by 24

Venetoclax-based Rational Combinations are Effective in Models of MYCN -amplified Neuroblastoma

Dalton, K. M., Krytska, K., Lochmann, T. L., Sano, R., Casey, C. E., D'Aulerio, A., Khan, Q. A., Crowther, G. S., Coon, C. M., Cai, J., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0710 · Cited by 26

Synergistic activity of combined inhibition of anti-apoptotic molecules in B-cell precursor ALL

Seyfried, F., Stirnweiß, F. U., Niedermayer, A., Enzenmüller, S., Hörl, R. L., Münch, V., Köhrer, S., Debatin, K., & Meyer, L. H. (2022) · Leukemia · doi:10.1038/s41375-021-01502-z · Cited by 24

Targeting the apoptosis pathway to treat tumours of the paediatric nervous system

Fitzgerald, M.-C., O’Halloran, P. J., Connolly, N. M. C., & Murphy, B. M. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04900-y · Cited by 26

Activation of the PP2A-B56α heterocomplex synergizes with venetoclax therapies in AML through BCL2 and MCL1 modulation

Peris, I., Romero-Murillo, S., Martínez‐Balsalobre, E., Farrington, C. C., Arriazu, E., Marcotegui, N., Jiménez-Muñoz, M., Alburquerque-Prieto, C., Torres-López, A., Fresquet, V. J., et al. (2022) · Blood · doi:10.1182/blood.2022016466 · Cited by 24

Targeting Mcl-1 Degradation by Bergenin Inhibits Tumorigenesis of Colorectal Cancer Cells

Gan, Y., Li, X., Han, S., Zhou, L. Q., & Li, W. (2023) · Pharmaceuticals · doi:10.3390/ph16020241 · Cited by 24

Lymphoma cells lacking pro-apoptotic BAX are highly resistant to BH3-mimetics targeting pro-survival MCL-1 but retain sensitivity to conventional DNA-damaging drugs

Diepstraten, S. T., Young, S., Marca, J. E. L., Wang, Z., Kluck, R. M., Strasser, A., & Kelly, G. L. (2023) · Cell Death and Differentiation · doi:10.1038/s41418-023-01117-0 · Cited by 24

Targeting regulated cell death pathways in acute myeloid leukemia

Garciaz, S., Miller, T. W., Collette, Y., & Vey, N. (2023) · Cancer Drug Resistance · doi:10.20517/cdr.2022.108 · Cited by 25

Optimized induction of mitochondrial apoptosis for chemotherapy-free treatment of BCR-ABL+acute lymphoblastic leukemia

Scherr, M., Kirchhoff, H., Battmer, K., Wohlan, K., Lee, C.-W., Ricke‐Hoch, M., Erschow, S., Law, E. W. P., Kloos, A., Heuser, M., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0315-6 · Cited by 24

Confounding off-target effects of BH3 mimetics at commonly used concentrations: MIM1, UMI-77, and A-1210477

Mallick, D. J., Soderquist, R. S., Bates, D. J. P., & Eastman, A. R. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1426-3 · Cited by 24

Antileukemic efficacy of a potent artemisinin combined with sorafenib and venetoclax

Moses, B. S., McCullough, S., Fox, J. M., Mott, B. T., Bentzen, S. M., Kim, M.-J., Tyner, J. W., Lapidus, R. G., Emadi, A., Rudek, M. A., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003429 · Cited by 24

Cytokine-like protein 1–induced survival of monocytes suggests a combined strategy targeting MCL1 and MAPK in CMML

Sevin, M., Debeurme, F., Laplane, L., Badel, S., Morabito, M., Newman, H., Torres‐Martín, M., Yang, Q., Badaoui, B., Wagner‐Ballon, O., et al. (2021) · Blood · doi:10.1182/blood.2020008729 · Cited by 24

Single-cell RNA sequencing and machine learning provide candidate drugs against drug-tolerant persister cells in colorectal cancer

Nojima, Y., Yao, R., & Suzuki, T. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2025.167693 · Cited by 23

Precision Targeting of BFL-1/A1 and an ATM Co-dependency in Human Cancer

Guerra, R. M., Bird, G. H., Harvey, E. P., Dharia, N. V., Korshavn, K. J., Prew, M. S., Stegmaier, K., & Walensky, L. D. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.08.089 · Cited by 23

Pediatric multicellular tumor spheroid models illustrate a therapeutic potential by combining BH3 mimetics with Natural Killer (NK) cell-based immunotherapy

Särchen, V., Shanmugalingam, S., Kehr, S., Reindl, L. M., Grèze, V., Wiedemann, S., Boedicker, C., Jacob, M., Bankov, K., Becker, N., et al. (2022) · Cell Death Discovery · doi:10.1038/s41420-021-00812-6 · Cited by 25

BCL-XL inhibition induces an FGFR4-mediated rescue response in colorectal cancer

Ramesh, P., Franco, S. D., Taboada, L. A., Zhang, L., Nicotra, A., Stassi, G., & Medema, J. P. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110374 · Cited by 23

Novel covalent CDK7 inhibitor potently induces apoptosis in acute myeloid leukemia and synergizes with Venetoclax

Gaur, T., Poddutoori, R., Khare, L., Bagal, B. P., Rashmi, S., Patkar, N. V., Tembhare, P. R., Subramanian, P. G., Shetty, D. L., Dutt, A., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02750-w · Cited by 23

Targeted regulated cell death with small molecule compounds in colorectal cancer: Current perspectives of targeted therapy and molecular mechanisms

Li, R., Wu, Y., Li, Y., Wen, S., Wang, A., Zhu, Y., Hu, X., Xia, Y., Ouyang, L., & Wang, G. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.116040 · Cited by 23

Targeting intermediary metabolism enhances the efficacy of BH3 mimetic therapy in hematologic malignancies

Al-Zebeeby, A., Vogler, M., Milani, M., Richards, C., Alotibi, A., Greaves, G., Dyer, M. J. S., Cohen, G. M., & Varadarajan, S. (2018) · Haematologica · doi:10.3324/haematol.2018.204701 · Cited by 22

BH3 Mimetics for the Treatment of B-Cell Malignancies—Insights and Lessons from the Clinic

Lin, V. S., Xu, Z., Huang, D. C. S., & Thijssen, R. (2020) · Cancers · doi:10.3390/cancers12113353 · Cited by 24

Physiological Functions of Mcl-1: Insights From Genetic Mouse Models

Chin, H. S., & Fu, N. Y. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.704547 · Cited by 22

Apoferritin-Encapsulated Jerantinine A for Transferrin Receptor Targeting and Enhanced Selectivity in Breast Cancer Therapy

Abuzaid, H., Abdelrazig, S., Ferreira, L., Collins, H. M., Kim, D., Lim, K., Kam, T., Turyanska, L., & Bradshaw, T. D. (2022) · ACS Omega · doi:10.1021/acsomega.2c00997 · Cited by 22

Generation of a CRISPR activation mouse that enables modelling of aggressive lymphoma and interrogation of venetoclax resistance

Deng, Y., Diepstraten, S. T., Potts, M. A., Giner, G., Trezise, S., Ng, A. P., Healey, G., Kane, S. R., Cooray, A., Behrens, K., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32485-9 · Cited by 22

Endogenous and imposed determinants of apoptotic vulnerabilities in cancer

Sarosiek, K. A., & Wood, K. C. (2022) · Trends in cancer · doi:10.1016/j.trecan.2022.10.004 · Cited by 23

Synergistic combination therapy delivered via layer‐by‐layer nanoparticles induces solid tumor regression of ovarian cancer

Kong, S. M., Moharil, P., Handly‐Santana, A., Boehnke, N., Panayiotou, R., Gomerdinger, V. F., Covarrubias, G., Pires, I. S., Zervantonakis, I. K., Brugge, J. S., et al. (2022) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10429 · Cited by 22

Regulatory role of RBM39 in acute myeloid leukemia: Mediation through the PI3K/AKT pathway

Zhang, X., Yang, L., Liu, X., Nie, Z.-Y., Liu, M., Wang, T., Lu, Y., Pan, Y., Zhan, Y., Wang, Z., et al. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2023.119607 · Cited by 23

Histidine-Covalent Stapled Alpha-Helical Peptides Targeting hMcl-1

Alboreggia, G., Udompholkul, P., Baggio, C., Muzzarelli, K. M., Assar, Z., & Pellecchia, M. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00277 · Cited by 22

Low BCL-xL expression in triple-negative breast cancer cells favors chemotherapy efficacy, and this effect is limited by cancer-associated fibroblasts

Nocquet, L., Roul, J., Lefebvre, C. C., Duarte, L., Campone, M., Juin, P. P., & Souazé, F. (2024) · Scientific Reports · doi:10.1038/s41598-024-64696-z · Cited by 22

Repurposing of mTOR Complex Inhibitors Attenuates MCL-1 and Sensitizes to PARP Inhibition

Mattoo, A. R., Joun, A., & Jessup, J. M. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0650 · Cited by 23

Anaplastic Lymphoma Kinase Confers Resistance to BRAF Kinase Inhibitors in Melanoma

Janoštiak, R., Malvi, P., & Wajapeyee, N. (2019) · iScience · doi:10.1016/j.isci.2019.06.001 · Cited by 22

Combination of fenretinide and ABT-263 induces apoptosis through NOXA for head and neck squamous cell carcinoma treatment

Britt, E., Raman, S., Leek, K., Sheehy, C. H., Kim, S. W., & Harada, H. (2019) · PLoS ONE · doi:10.1371/journal.pone.0219398 · Cited by 22

BH3 mimetics potentiate pro-apoptotic activity of encorafenib in BRAFV600E melanoma cells

Hartman, M. L., Gajos-Michniewicz, A., Talaj, J. A., Mielczarek-Lewandowska, A., & Czyż, M. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.11.036 · Cited by 22

Synergistic Action of MCL-1 Inhibitor with BCL-2/BCL-XL or MAPK Pathway Inhibitors Enhances Acute Myeloid Leukemia Cell Apoptosis and Differentiation

Opydo‐Chanek, M., Mlyczyńska, A., Mlyczyńska, E., Rak, A., & Kołaczkowska, E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087180 · Cited by 21

Mitochondrial bioenergetics as a cell fate rheostat for responsive to Bcl-2 drugs: New cues for cancer chemotherapy

Palominos, C., Fuentes-Retamal, S., Salazar, J. P., Guzmán‐Rivera, D., Correa, P., Mellado, M., Araya‐Maturana, R., & Urra, F. A. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216965 · Cited by 21

Apoptotic priming in senescence predicts specific senolysis by quantitative analysis of mitochondrial dependencies

MacDonald, J. A., Bradshaw, G. A., Jochems, F., Bernards, R., & Letai, A. G. (2025) · Cell Death and Differentiation · doi:10.1038/s41418-024-01431-1 · Cited by 26

Heterogeneous modulation of Bcl-2 family members and drug efflux mediate MCL-1 inhibitor resistance in multiple myeloma

Bolomsky, A., Miettinen, J. J., Malyutina, A., Bešše, A., Huber, J., Fellinger, S., Breid, H., Parsons, A., Klavins, K., Hannich, J. T., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003826 · Cited by 21

PALVEN: Phase Ib Trial of Palbociclib, Letrozole and Venetoclax in Estrogen Receptor- and BCL2-Positive Advanced Breast Cancer

Muttiah, C., Whittle, J. R., Oakman, C. A., & Lindeman, G. J. (2022) · Future Oncology · doi:10.2217/fon-2021-1450 · Cited by 21

Exploiting endogenous and therapy-induced apoptotic vulnerabilities in immunoglobulin light chain amyloidosis with BH3 mimetics

Fraser, C. S., Spetz, J. K. E., Qin, X., Presser, A. G., Choiniere, J., Li, C., Yu, S. J., Blevins, F., Hata, A. N., Miller, J. W., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33461-z · Cited by 21

Pharmacological Targeting of Bcl-2 Induces Caspase 3-Mediated Cleavage of HDAC6 and Regulates the Autophagy Process in Colorectal Cancer

Yang, D., He, L., Ma, S.-Q., Li, S., Zhang, Y., Hu, C., Huang, J., Xu, Z., Tang, D., & Chen, Z. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076662 · Cited by 21

Platinum-Based Mcl-1 Inhibitor Targeting Mitochondria Achieves Enhanced Antitumor Activity as a Single Agent or in Combination with ABT-199

Lü, X., Wu, M., Wu, J.-L., Zhang, H.-Q., Liang, H., & Chen, Z. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00355 · Cited by 21

A rare subgroup of leukemia stem cells harbors relapse-inducing potential in acute lymphoblastic leukemia

Senft, D., & Jeremias, I. (2018) · Experimental Hematology · doi:10.1016/j.exphem.2018.09.006 · Cited by 23

Role of Mcl-1 in regulation of cell death in human induced pluripotent stem cell-derived cardiomyocytes in vitro

Guo, L., Eldridge, S. R., Furniss, M. J., Mussio, J., & Davis, M. (2018) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2018.09.041 · Cited by 22

Resveratrol Enhances mRNA and siRNA Lipid Nanoparticles Primary CLL Cell Transfection

Kon, E., Hazan‐Halevy, I., Rosenblum, D., Cohen, N., Chatterjee, S., Veiga, N., Raanani, P., Bairey, O., Benjamini, O., Nagler, A., et al. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12060520 · Cited by 21

Phosphatase PP2A enhances MCL-1 protein half-life in multiple myeloma cells

Slomp, A., Moesbergen, L. M., Eldering, E., Kersten, M. J., Minnema, M. C., & Peperzak, V. (2021) · Cell Death and Disease · doi:10.1038/s41419-020-03351-7 · Cited by 22

CHK2 Inhibition Provides a Strategy to Suppress Hematologic Toxicity from PARP Inhibitors

Xu, Z., Vandenberg, C. J., Lieschke, E., Rago, L. D., Scott, C. L., & Majewski, I. J. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0791 · Cited by 22

The BH3-only protein NOXA serves as an independent predictor of breast cancer patient survival and defines susceptibility to microtubule targeting agents

Karbon, G., Haschka, M. D., Hackl, H., Soratroi, C., Rocamora‐Reverte, L., Parson, W., Fiegl, H., & Villunger, A. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04415-y · Cited by 21

Therapeutic inhibition of BCL-2 and related family members

Levy, M., & Claxton, D. F. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1290078 · Cited by 20

Synergistic anti-proliferative effects of combination of ABT-263 and MCL-1 selective inhibitor A-1210477 on cervical cancer cell lines

Lian, B. S. X., Yek, A. E. H., Shuvas, H., Rahman, S. F. A., Muniandy, K., & Mohana‐Kumaran, N. (2018) · BMC Research Notes · doi:10.1186/s13104-018-3302-0 · Cited by 20

Co‐targeting bromodomain and extra‐terminal proteins and MCL1 induces synergistic cell death in melanoma

Tseng, H., Dreyer, J., Emran, A. A., Gunatilake, D., Pirozyan, M. R., Cullinane, C. M., Dutton‐Regester, K., Rizos, H., Hayward, N. K., McArthur, G. A., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.33000 · Cited by 20

BCL-XL inhibition by BH3-mimetic drugs induces apoptosis in models of Epstein-Barr virus-associated T/NK-cell lymphoma.

Sejic, N., George, L. C., Tierney, R. J., Chang, C. W. T., Kondrashova, O., MacKinnon, R. N., Lan, P., Bell, A. I., Lessène, G., Long, H. M., et al. (2020) · PubMed Central · doi:10.1182/bloodadvances.2020002446 · Cited by 20

BCL-XL is an actionable target for treatment of malignant pleural mesothelioma

Arulananda, S., O’Brien, M., Evangelista, M., Harris, T. J., Steinohrt, N. S., Jenkins, L. J., Walkiewicz, M., O’Donoghue, R. J. J., Poh, A. R., Thapa, B., et al. (2020) · Cell Death Discovery · doi:10.1038/s41420-020-00348-1 · Cited by 22

Urinary Tract Tumor Organoids Reveal Eminent Differences in Drug Sensitivities When Compared to 2-Dimensional Culture Systems

Wei, Y., Amend, B., Todenhöfer, T., Lipke, N., Aicher, W. K., Fend, F., Stenzl, A., & Harland, N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23116305 · Cited by 20

Scaffold hopping from indoles to indazoles yields dual MCL-1/BCL-2 inhibitors from MCL-1 selective leads

Drennen, B., Goodis, C. C., Bowen, N. G., Yu, W., Vickers, G. E. A., Wilder, P. T., MacKerell, A. D., & Fletcher, S. (2022) · RSC Medicinal Chemistry · doi:10.1039/d2md00095d · Cited by 20

Targeting of MCL-1 in breast cancer-associated fibroblasts reverses their myofibroblastic phenotype and pro-invasive properties

Bonneaud, T. L., Lefebvre, C. C., Nocquet, L., Basseville, A., Roul, J., Weber, H., Campone, M., Juin, P. P., & Souazé, F. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05214-9 · Cited by 23

BH3 mimetics efficiently induce apoptosis in mouse basophils and mast cells

Reinhart, R., Rohner, L., Wicki, S., Fux, M., & Kaufmann, T. (2017) · Cell Death and Differentiation · doi:10.1038/cdd.2017.154 · Cited by 20

MCL1 binding to the reverse BH3 motif of P18INK4C couples cell survival to cell proliferation

Whitaker, R. H., & Placzek, W. J. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2351-1 · Cited by 20

Functional apoptosis profiling identifies MCL-1 and BCL-xL as prognostic markers and therapeutic targets in advanced thymomas and thymic carcinomas

Müller, D., Mazzeo, P., Koch, R., Bösherz, M.-S., Welter, S., von Hammerstein-Equord, A. F., Hinterthaner, M., Cordes, L., Belharazem, D., Marx, A., et al. (2021) · BMC Medicine · doi:10.1186/s12916-021-02158-3 · Cited by 20

MCL1 Can Be Targeted to Induce Apoptosis in Multiple Cancer Types

(2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-rw2016-207

Abstract 4482: S64315 (MIK665) is a potent and selective Mcl1 inhibitor with strong antitumor activity across a diverse range of hematologic tumor models

Maragno, A. L., Mistry, P., Kotschy, A., Szlavik, Z., Murray, J., Davidson, J. E. P., Toumelin-Braizat, G. L., Chanrion, M., Bruno, A., Clapéron, A., et al. (2019) · Cancer Research · doi:10.1158/1538-7445.am2019-4482 · Cited by 15

Development and Characterization of Novel Mcl-1 Inhibitors for Treatment of Cancer.

Mady, A. S. A. (2016) · Deep Blue (University of Michigan) · Cited by 1

Targeting MCL-1 in cancer: current status and perspectives

Wang, H., Guo, M., Wei, H., & Chen, Y. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01079-1 · Cited by 318

Targeting MCL‐1 to Overcome Therapeutic Resistance and Improve Cancer Mortality

Mohiuddin, M. (2025) · Health Science Reports · doi:10.1002/hsr2.71390 · Cited by 9